secwatch.observer — SEC 8-K summary
======================================

Issuer:     Quoin Pharmaceuticals, Ltd. (QNRX)
CIK:        0001671502
Form:       8-K
Filed at:   2023-12-18T23:59:59+00:00
Accession:  0001104659-23-126974
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Quoin receives FDA clearance to expand QRX003 trials; blinded trial to 30 subjects, dose changed to 4% twice daily
--------------------------------------------------------------------------------

- FDA cleared protocol amendments for both ongoing QRX003 trials for Netherton Syndrome.
- Blinded trial increased from 18 to 30 subjects; lower 2% dose eliminated, all now receive 4% QRX003 or placebo twice daily.
- Open-label trial expanded from 10 to 20 subjects; dosing frequency changed to twice daily with continued off-label systemic therapy.
- Decision based on positive initial data and clean safety profile; all clinical endpoints unchanged.
- Quoin plans to open additional clinical sites to accommodate increased enrollment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1671502/000110465923126974/0001104659-23-126974-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1671502/000110465923126974/tm2333160d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-126974

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer